BACKGROUND: Helical tomotherapy is a novel intensity-modulated radiotherapy modality with a helical 360° radiation delivery system and CT imaging ability. The purpose of this report is to review our initial experiences and to assess the toxicity and efficacy of helical tomotherapy for esophageal cancer. METHODS: Twenty patients with locally advanced esophageal cancer (T3-4 and/or N+ and/or M1a/b) were treated with helical tomotherapy. Radiotherapy included simultaneous 50 Gy to gross tumorous areas and 45 Gy to areas of suspected subclinical disease. All received combination chemotherapy. Ten patients underwent surgical resection after completion of chemoradiation. Ten patients were ineligible for surgery. RESULTS: The treatment was well-tolerated. There were no treatment-related deaths or Grade 4 toxicity. Grade 3 toxicities were noted in 9 of 20 patients (45%). Down-staging was noted in 7 of 10 patients (70%) who underwent surgery. The median follow-up time was 24.5 months. Eight patients, including 3 with surgery and 5 without surgery, have died. The 1-year overall survival rates for the entire group, patients with and without surgical resection are 80.0%, 100.0% and 60.0% respectively (log-rank p = 0.244, surgery versus no surgery). CONCLUSIONS: The regimen of combined chemoradiation by helical tomotherapy for locally advanced esophageal cancer is well-tolerated. The toxicity profile compares favorably with that of protocols based on conventional approach and the preliminary indications of efficacy are encouraging.
BACKGROUND: Helical tomotherapy is a novel intensity-modulated radiotherapy modality with a helical 360° radiation delivery system and CT imaging ability. The purpose of this report is to review our initial experiences and to assess the toxicity and efficacy of helical tomotherapy for esophageal cancer. METHODS: Twenty patients with locally advanced esophageal cancer (T3-4 and/or N+ and/or M1a/b) were treated with helical tomotherapy. Radiotherapy included simultaneous 50 Gy to gross tumorous areas and 45 Gy to areas of suspected subclinical disease. All received combination chemotherapy. Ten patients underwent surgical resection after completion of chemoradiation. Ten patients were ineligible for surgery. RESULTS: The treatment was well-tolerated. There were no treatment-related deaths or Grade 4 toxicity. Grade 3 toxicities were noted in 9 of 20 patients (45%). Down-staging was noted in 7 of 10 patients (70%) who underwent surgery. The median follow-up time was 24.5 months. Eight patients, including 3 with surgery and 5 without surgery, have died. The 1-year overall survival rates for the entire group, patients with and without surgical resection are 80.0%, 100.0% and 60.0% respectively (log-rank p = 0.244, surgery versus no surgery). CONCLUSIONS: The regimen of combined chemoradiation by helical tomotherapy for locally advanced esophageal cancer is well-tolerated. The toxicity profile compares favorably with that of protocols based on conventional approach and the preliminary indications of efficacy are encouraging.
Authors: J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud Journal: N Engl J Med Date: 1997-07-17 Impact factor: 91.245
Authors: Marco van Vulpen; Colin Field; Cornelis P J Raaijmakers; Matthew B Parliament; Chris H J Terhaard; Marc A MacKenzie; Rufus Scrimger; Jan J W Lagendijk; B Gino Fallone Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: Yi-Jen Chen; An Liu; Chunhui Han; Peter T Tsai; Timothy E Schultheiss; Richard D Pezner; Nilesh Vora; Dean Lim; Stephen Shibata; Kemp H Kernstine; Jeffrey Y C Wong Journal: Med Dosim Date: 2007 Impact factor: 1.482
Authors: Yi-Jen Chen; Chunhui Han; An Liu; Timothy E Schultheiss; Kemp H Kernstine; Stephen Shibata; Nayana L Vora; Richard D Pezner; Jeffrey Y C Wong Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-25 Impact factor: 7.038
Authors: Nam P Nguyen; Siyoung Jang; Jacqueline Vock; Vincent Vinh-Hung; Alexander Chi; Paul Vos; Judith Pugh; Richard A Vo; Misty Ceizyk; Anand Desai; Lexie Smith-Raymond Journal: BMC Cancer Date: 2014-04-17 Impact factor: 4.430